Interestingly, recognizing the wake-promoting capacity of histamine H3R antagonists in combination with the “caffeine-like effects” of adenosine A1R/A2AR antagonists, multitargeting ligands were developed to achieve comprehensive therapies of motor disorders such as Parkinson’s disease (PD). Here, ADORA2A is linked to Parkinson disease.